{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:08:06Z","timestamp":1790168886840,"version":"4.1.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"22","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antiangiogenesis therapies for the treatment of cancers hold the promise of high efficacy and low toxicity. In vivo phage display was used to identify peptides specifically targeting tumor blood vessels. The peptide SP5-52 recognized tumor neovasculature but not normal blood vessels in severe combined immunodeficiency mice bearing human tumors. Synthetic peptide was shown to inhibit the binding of PC5-52 phage particles to the tumor mass in the competitive inhibition assay. Several selected phage clones displayed the consensus motif, proline-serine-proline, and this motif was crucial for peptide binding to the tumor neovasculature. SP5-52 peptides also bound vascular endothelial growth factor\u2013stimulated human umbilical vein endothelial cells and blood vessels of human lung cancer surgical specimens. Furthermore, this targeting phage was shown to home to tumor tissues from eight different types of human tumor xenografts following in vivo phage display experiments. An SP5-52 peptide-linked liposome carrying doxorubicin enhanced the therapeutic efficacy of the drug, markedly decreased tumor blood vessels, and resulted in higher survival rates of human lung and oral cancer\u2013bearing xenograft mice. The current study indicates that ligand-targeted therapy offers improved therapeutic effects over conventional anticancer drug therapy, and that the peptide SP5-52 specifically targets tumor neovasculature and is a good candidate for targeted drug delivery to solid tumors. [Cancer Res 2007;67(22):10958\u201365]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-2233","type":"journal-article","created":{"date-parts":[[2007,11,15]],"date-time":"2007-11-15T15:23:37Z","timestamp":1195140217000},"page":"10958-10965","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug Delivery"],"prefix":"10.1158","volume":"67","author":[{"given":"Tong-Young","family":"Lee","sequence":"first","affiliation":[{"name":"1Institute of Pathology, College of Medicine, National Taiwan University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Tarng","family":"Lin","sequence":"additional","affiliation":[{"name":"1Institute of Pathology, College of Medicine, National Taiwan University;"},{"name":"2Department of Pathology, National Taiwan University Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Yao","family":"Kuo","sequence":"additional","affiliation":[{"name":"3Institute of Cellular and Organismic Biology, Academia Sinica; Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Kuan","family":"Chang","sequence":"additional","affiliation":[{"name":"1Institute of Pathology, College of Medicine, National Taiwan University;"},{"name":"3Institute of Cellular and Organismic Biology, Academia Sinica; Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chung","family":"Wu","sequence":"additional","affiliation":[{"name":"1Institute of Pathology, College of Medicine, National Taiwan University;"},{"name":"3Institute of Cellular and Organismic Biology, Academia Sinica; Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,11,15]]},"reference":[{"key":"2022061623190445900_B1","doi-asserted-by":"crossref","unstructured":"Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest\u20082003; 111: 1287\u201395.","DOI":"10.1172\/JCI200317929"},{"key":"2022061623190445900_B2","doi-asserted-by":"crossref","unstructured":"Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer\u20082002; 2: 83\u201390.","DOI":"10.1038\/nrc724"},{"key":"2022061623190445900_B3","doi-asserted-by":"crossref","unstructured":"Eliceiri BP, Cheresh DA. The role of \u03b1v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest\u20081999; 103: 1227\u201330.","DOI":"10.1172\/JCI6869"},{"key":"2022061623190445900_B4","doi-asserted-by":"crossref","unstructured":"Pasqualini R, Koivunen E, Ruoslahti E. \u03b1v Integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol\u20081997; 15: 542\u20136.","DOI":"10.1038\/nbt0697-542"},{"key":"2022061623190445900_B5","doi-asserted-by":"crossref","unstructured":"Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science\u20081998; 279: 377\u201380.","DOI":"10.1126\/science.279.5349.377"},{"key":"2022061623190445900_B6","doi-asserted-by":"crossref","unstructured":"Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet\u20081988; 15: 15\u201331.","DOI":"10.2165\/00003088-198815010-00002"},{"key":"2022061623190445900_B7","doi-asserted-by":"crossref","unstructured":"Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev\u20081999; 51: 691\u2013743.","DOI":"10.1016\/S0031-6997(24)01426-1"},{"key":"2022061623190445900_B8","doi-asserted-by":"crossref","unstructured":"Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A\u20081991; 88: 11460\u20134.","DOI":"10.1073\/pnas.88.24.11460"},{"key":"2022061623190445900_B9","doi-asserted-by":"crossref","unstructured":"Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer\u20081994; 73: 1478\u201384.","DOI":"10.1002\/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1"},{"key":"2022061623190445900_B10","doi-asserted-by":"crossref","unstructured":"Colbern GT, Hiller A, Musterer RS, Pegg E, Henderson IC, Working P. Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes. J Liposome Res\u20081999; 9: 523\u201338.","DOI":"10.3109\/08982109909035551"},{"key":"2022061623190445900_B11","unstructured":"Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res\u20081994; 54: 987\u201392."},{"key":"2022061623190445900_B12","unstructured":"Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a Pediatric Oncology Group Study. Clin Cancer Res\u20082002; 8: 413\u20138."},{"key":"2022061623190445900_B13","doi-asserted-by":"crossref","unstructured":"Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2. Ann Oncol\u20082000; 11: 1029\u201333.","DOI":"10.1023\/A:1008365716693"},{"key":"2022061623190445900_B14","doi-asserted-by":"crossref","unstructured":"Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs\u20081997; 54: 15\u201321.","DOI":"10.2165\/00003495-199700544-00005"},{"key":"2022061623190445900_B15","unstructured":"Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells\u20081991; 3: 77\u201385."},{"key":"2022061623190445900_B16","doi-asserted-by":"crossref","unstructured":"Shockley TR, Lin K, Nagy JA, Tompkins RG, Dvorak HF, Yarmush ML. Penetration of tumor tissue by antibodies and other immunoproteins. Ann N Y Acad Sci\u20081991; 618: 367\u201382.","DOI":"10.1111\/j.1749-6632.1991.tb27257.x"},{"key":"2022061623190445900_B17","doi-asserted-by":"crossref","unstructured":"Fu Y, Shearing LN, Haynes S, et al. Isolation from phage display libraries of single chain variable fragment antibodies that recognize conformational epitopes in the malaria vaccine candidate, apical membrane antigen-1. J Biol Chem\u20081997; 272: 25678\u201384.","DOI":"10.1074\/jbc.272.41.25678"},{"key":"2022061623190445900_B18","doi-asserted-by":"crossref","unstructured":"Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science\u20081990; 249: 386\u201390.","DOI":"10.1126\/science.1696028"},{"key":"2022061623190445900_B19","doi-asserted-by":"crossref","unstructured":"Wu HC, Huang YL, Chao TT, et al. Identification of B-cell epitope of dengue virus type 1 and its application in diagnosis of patients. J Clin Microbiol\u20082001; 39: 977\u201382.","DOI":"10.1128\/JCM.39.3.977-982.2001"},{"key":"2022061623190445900_B20","doi-asserted-by":"crossref","unstructured":"Wu HC, Jung MY, Chiu CY, et al. Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. J Gen Virol\u20082003; 84: 2771\u20139.","DOI":"10.1099\/vir.0.19228-0"},{"key":"2022061623190445900_B21","doi-asserted-by":"crossref","unstructured":"Atwell S, Ultsch M, De Vos AM, Wells JA. Structural plasticity in a remodeled protein-protein interface. Science\u20081997; 278: 1125\u20138.","DOI":"10.1126\/science.278.5340.1125"},{"key":"2022061623190445900_B22","unstructured":"Bottger V, Bottger A, Howard SF, et al. Identification of novel mdm2 binding peptides by phage display. Oncogene\u20081996; 13: 2141\u20137."},{"key":"2022061623190445900_B23","doi-asserted-by":"crossref","unstructured":"Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an \u03b1-helical bacterial receptor domain. Nat Biotechnol\u20081997; 15: 772\u20137.","DOI":"10.1038\/nbt0897-772"},{"key":"2022061623190445900_B24","doi-asserted-by":"crossref","unstructured":"Li B, Tom JY, Oare D, et al. Minimization of a polypeptide hormone. Science\u20081995; 270: 1657\u201360.","DOI":"10.1126\/science.270.5242.1657"},{"key":"2022061623190445900_B25","doi-asserted-by":"crossref","unstructured":"Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science\u20081996; 273: 458\u201364.","DOI":"10.1126\/science.273.5274.458"},{"key":"2022061623190445900_B26","doi-asserted-by":"crossref","unstructured":"Castano AR, Tangri S, Miller JE, et al. Peptide binding and presentation by mouse CD1. Science\u20081995; 269: 223\u20136.","DOI":"10.1126\/science.7542403"},{"key":"2022061623190445900_B27","doi-asserted-by":"crossref","unstructured":"Kraft S, Diefenbach B, Mehta R, Jonczyk A, Luckenbach GA, Goodman SL. Definition of an unexpected ligand recognition motif for \u03b1v \u03b26 integrin. J Biol Chem\u20081999; 274: 1979\u201385.","DOI":"10.1074\/jbc.274.4.1979"},{"key":"2022061623190445900_B28","doi-asserted-by":"crossref","unstructured":"Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol\u20081995; 130: 1189\u201396.","DOI":"10.1083\/jcb.130.5.1189"},{"key":"2022061623190445900_B29","doi-asserted-by":"crossref","unstructured":"Folgori A, Tafi R, Meola A, et al. A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera. EMBO J\u20081994; 13: 2236\u201343.","DOI":"10.1002\/j.1460-2075.1994.tb06501.x"},{"key":"2022061623190445900_B30","doi-asserted-by":"crossref","unstructured":"Prezzi C, Nuzzo M, Meola A, et al. Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients. J Immunol\u20081996; 156: 4504\u201313.","DOI":"10.4049\/jimmunol.156.11.4504"},{"key":"2022061623190445900_B31","doi-asserted-by":"crossref","unstructured":"Liu IJ, Hsueh PR, Lin CT, et al. Disease-specific B cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens. J Infect Dis\u20082004; 190: 797\u2013809.","DOI":"10.1086\/422753"},{"key":"2022061623190445900_B32","doi-asserted-by":"crossref","unstructured":"Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med\u20081996; 2: 299\u2013305.","DOI":"10.1038\/nm0396-299"},{"key":"2022061623190445900_B33","doi-asserted-by":"crossref","unstructured":"Lee TY, Wu HC, Tseng YL, Lin CT. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res\u20082004; 64: 8002\u20138.","DOI":"10.1158\/0008-5472.CAN-04-1948"},{"key":"2022061623190445900_B34","doi-asserted-by":"crossref","unstructured":"Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature\u20081996; 380: 364\u20136.","DOI":"10.1038\/380364a0"},{"key":"2022061623190445900_B35","doi-asserted-by":"crossref","unstructured":"Chu YW, Yang PC, Yang SC, et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol\u20081997; 17: 353\u201360.","DOI":"10.1165\/ajrcmb.17.3.2837"},{"key":"2022061623190445900_B36","doi-asserted-by":"crossref","unstructured":"Tseng YL, Hong RL, Tao MH, Chang FH. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer\u20081999; 80: 723\u201330.","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<723::AID-IJC16>3.0.CO;2-L"},{"key":"2022061623190445900_B37","doi-asserted-by":"crossref","unstructured":"Habeeb AFSA. Determination of free amino groups in protein by trinitrobenzene sulfuric acid. Anal Biochem\u20081966; 14: 328.","DOI":"10.1016\/0003-2697(66)90275-2"},{"key":"2022061623190445900_B38","doi-asserted-by":"crossref","unstructured":"Zalipsky S, Mullah N, Harding JA, Gittelman J, Guo L, DeFrees SA. Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug Chem\u20081997; 8: 111\u20138.","DOI":"10.1021\/bc9600832"},{"key":"2022061623190445900_B39","doi-asserted-by":"crossref","unstructured":"Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry\u20081997; 36: 66\u201375.","DOI":"10.1021\/bi962148u"},{"key":"2022061623190445900_B40","unstructured":"Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res\u20082002; 8: 1172\u201381."},{"key":"2022061623190445900_B41","doi-asserted-by":"crossref","unstructured":"Oku N, Asai T, Watanabe K, et al. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene\u20082002; 21: 2662\u20139.","DOI":"10.1038\/sj.onc.1205347"},{"key":"2022061623190445900_B42","doi-asserted-by":"crossref","unstructured":"Hoffman JA, Giraudo E, Singh M, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell\u20082003; 4: 383\u201391.","DOI":"10.1016\/S1535-6108(03)00273-3"},{"key":"2022061623190445900_B43","doi-asserted-by":"crossref","unstructured":"Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature\u20081997; 390: 404\u20137.","DOI":"10.1038\/37126"},{"key":"2022061623190445900_B44","doi-asserted-by":"crossref","unstructured":"Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol\u20081993; 66: 181\u201396.","DOI":"10.1259\/0007-1285-66-783-181"},{"key":"2022061623190445900_B45","doi-asserted-by":"crossref","unstructured":"Burrows FJ, Thorpe PE. Vascular targeting: a new approach to the therapy of solid tumors. Pharmacol Ther\u20081994; 64: 155\u201374.","DOI":"10.1016\/0163-7258(94)90037-X"},{"key":"2022061623190445900_B46","doi-asserted-by":"crossref","unstructured":"Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure\u2014an obstacle in cancer therapy. Nat Rev Cancer\u20082004; 4: 806\u201313.","DOI":"10.1038\/nrc1456"},{"key":"2022061623190445900_B47","unstructured":"Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, Jain RK. Interstitial hypertension in human breast and colorectal tumors. Cancer Res\u20081992; 52: 6371\u20134."},{"key":"2022061623190445900_B48","doi-asserted-by":"crossref","unstructured":"Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res\u20081991; 51: 6691\u20134.","DOI":"10.1016\/B978-0-12-168561-4.50333-4"},{"key":"2022061623190445900_B49","unstructured":"Gutmann R, Leunig M, Feyh J, et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res\u20081992; 52: 1993\u20135."},{"key":"2022061623190445900_B50","unstructured":"Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res\u20081990; 50: 4478\u201384."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/22\/10958\/2576094\/10958.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/22\/10958\/2576094\/10958.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T06:59:57Z","timestamp":1737529197000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/22\/10958\/533788\/Peptide-Mediated-Targeting-to-Tumor-Blood-Vessels"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,15]]},"references-count":50,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2007,11,15]]},"published-print":{"date-parts":[[2007,11,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-2233","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22370013","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370007.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370007","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370010","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370010.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370013.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496230.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,15]]}}}